The diagnostic value of imaging Aβ plaques in Alzheimer’s disease (AD) has accelerated the development of fluorine-18 labeled radiotracers with a longer half-life for easier translation to clinical use. We have developed [18F]flotaza, which shows high binding to Aβ plaques in postmortem human AD brain slices with low white matter binding. We report the binding of [18F]flotaza in postmortem AD hippocampus compared to cognitively normal (CN) brains and the evaluation of [18F]flotaza in transgenic 5xFAD mice expressing Aβ plaques. [18F]Flotaza binding was assessed in well-characterized human postmortem brain tissue sections consisting of HP CA1-subiculum (HP CA1-SUB) regions in AD (n = 28; 13 male and 15 female) and CN subjects (n = 32; 16 male and 16 female). Adjacent slices were immunostained with anti-Aβ and analyzed using QuPath. In vitro and in vivo [18F]flotaza PET/CT studies were carried out in 5xFAD mice. Post-mortem human brain slices from all AD subjects were positively IHC stained with anti-Aβ. High [18F]flotaza binding was measured in the HP CA1-SUB grey matter (GM) regions compared to white matter (WM) of AD subjects with GM/WM > 100 in some subjects. The majority of CN subjects had no decipherable binding. Male AD exhibited greater WM than AD females (AD WM♂/WM♀ > 5; p < 0.001) but no difference amongst CN WM. In vitro studies in 5xFAD mice brain slices exhibited high binding [18F]flotaza ratios (>50 versus cerebellum) in the cortex, HP, and thalamus. In vivo, PET [18F]flotaza exhibited binding to Aβ plaques in 5xFAD mice with SUVR~1.4. [18F]Flotaza is a new Aβ plaque PET imaging agent that exhibited high binding to Aβ plaques in postmortem human AD. Along with the promising results in 5xFAD mice, the translation of [18F]flotaza to human PET studies may be worthwhile.
Nicotinic acetylcholinergic receptors (nAChRs), including the α4β2* subtype are involved in cognition, learning and memory and may be adversely affected in Alzheimer's disease (AD). In our efforts to consider translational use of [18F]nifene PET in AD, we report quantitative autoradiographic evaluation of α4β2* nAChRs using hippocampus-subiculum (HP-SUB) from cognitively normal (CN) and AD subjects. Brain slices were incubated in [18F]nifene for α4β2* nAChRs and adjacent sections were tested with [18F]flotaza for Aβ plaques and [125I]IPPI for tau. Anti-Aβ and anti-tau immunostaining were carried out on adjacent slices. Regions of interest were drawn and binding of [18F]nifene, [18F]flotaza and [125I]IPPI were quantified.All CN subjects exhibited significant [18F]nifene binding in the HP-SUB regions. Average [18F]nifene ratios of SUB to HP was 1.9, suggesting higher α4β2* nAChRs in the SUB versus HP regions. [18F]nifene binding did not change with aging in the female subjects, while the male subjects exhibited a weak positive correlation. There was a significant decrease in the binding of [18F]nifene in AD subjects compared to CN. Braak stage comparisons showed a decrease of [18F]nifene in stages V and VI, while [18F]flotaza and [125I]IPPI increased significantly. A negative correlation was observed between [18F]nifene vs [18F]flotaza and [18F]nifene vs [125I]IPPI across Braak stages I-VI. These findings suggest that α4β2* nAChR availability was effectively measured by [18F]nifene in the HP-SUB and was adversely affected by the presence of Aβ plaques and tau.
Background/Objectives: Alzheimer’s disease (AD) severely hinders cognitive function in the hippocampus (HP) and subiculum (SUB), impacting the expression of nicotinic acetylcholine receptors (nAChRs) such as the α7-subtype. To investigate α7 nAChRs as a potential PET imaging biomarker, we report the quantitative binding of [125I]α-Bungarotoxin ([125I]α-Bgtx) for binding to postmortem human AD (n = 29; 13 males, 16 females) HP compared to cognitively normal (CN) (n = 28; 13 male, 15 female) HP. Methods: For comparisons with common AD biomarkers, adjacent slices were anti-Aβ and anti-Tau immunostained for analysis using QuPath. Results: The [125I]α-Bgtx average SUB/HP ratio was 0.5 among the CN subjects, suggesting higher [125I]α-Bgtx binding in the HP gray matter regions. The AD subjects showed overall less binding than the CN subjects, with no statistical significance. A positive correlation was found in the [125I]α-Bgtx binding in the AD subjects as the age increased. The Braak stage comparisons of [125I]α-Bgtx were made with [18F]flotaza binding to Aβ plaques and [125I]IPPI binding to Tau. A positive correlation was found between [125I]α-Bgtx and [18F]flotaza and there was a negative correlation between [125I]α-Bgtx and [125I]IPPI, implicating intricate relationships between the different AD biomarkers. Conclusions: [125I]α-Bgtx shows complimentary potential as a α7 nAChR imaging agent but needs more preclinical assessments to confirm effectiveness for translational PET studies using α7 nAChR radioligands.
Nicotinic acetylcholine receptors (nAChRs) are involved in various central nervous system functions and have also been implicated in several neurodegenerative disorders. The heteromeric α4β2* and homomeric α7 are two major nAChR subtypes which have been studied in the brain using positron emission tomography (PET). Our comparative autoradiographic studies of the two receptor types in the mouse and rat brains show major differences in the thalamus (α4β2* >> α7), hippocampus (α7 >> α4β2*), and subiculum (α4β2* >> α7). A relatively newer heteromeric α7β2 nAChR subtype has been identified in the brain which may have a greater role in neurodegeneration. We report the development of KS7 (3-(2-(S)-azetidinylmethoxy)-5-(1,4-diaza-bicyclo[3.2.2]nonane)pyridine) which incorporates structural features of Nifzetidine (high affinity for α4β2* nAChR) and ASEM (high affinity for α7 nAChR) in an effort to target α7 and β2 subunits in α7β2 nAChR. KS7 exhibited higher affinities (IC50 = 50 to 172 nM) for [3H]cytisine radiolabeled sites and weaker affinities (IC50 = 10 μM) for [125I]-α-bungarotoxin radiolabeled rat brain sites in several brain regions. The weaker affinity of KS7 to α7 nAChR may suggest lack of binding at the α7 subunit of α7β2 nAChR. A radiolabeled derivative of KS7 may be required to identify any specific binding to brain regions suggested to contain α7β2 nAChR.
Parkinson’s disease (PD) involves motor and cognitive impairment that nicotinic acetylcholine receptors (nAChRs) such as the α7 subtype are responsible for regulating. The hippocampus, abundant in α7 nAChRs, was quantitatively evaluated for [125I]α-bungarotoxin ([125I]α-Bgtx) binding to α7 nAChRs in postmortem human PD (n = 26; 12 male, 14 female) and cognitively normal (CN) (n = 29; 14 male, 15 female) brain slices. Anti-ubiquitin and anti-α-synuclein immunostained adjacent slices were analyzed using QuPath. Autoradiographs of [125I]α-Bgtx radioligand binding were analyzed in OptiQuant. Ubiquitin and α-synuclein distribution generally aligned with the distribution of α7 nAChRs detected by [125I]α-Bgtx. Binding of [125I]α-Bgtx in PD cases was significantly greater than CN with a 32% increase in gray matter binding. A weak positive correlation between age and [125I]α-Bgtx binding was found in both PD and CN. In comparison to Alzheimer’s disease hippocampus, [125I]α-Bgtx binding in PD gray matter was higher by 41%. Differences in nAChR expression imply unique roles depending on the neurodegenerative pathology. PD may experience an increase in α7 nAChRs as a compensatory mechanism to the loss in neurons, highlighting its neuroprotective capabilities. [125I]α-Bgtx shows potential as a radioligand for α7 nAChRs to elucidate the complexities of PD pathology.
Non-motor symptoms in Parkinson’s disease (PD) may be influenced by the α4β2* subtype of nicotinic acetylcholine receptors (nAChR) present in the hippocampus and subiculum. To continue efforts in PET diagnostics for PD, autoradiographic [ 18 F]nifene binding to α4β2* nAChR was quantitively assessed in the hippocampus-subiculum (HP-SUB) of PD (n = 27; 14 males, 13 females) and cognitively normal (CN) (n = 32; 16 males, 16 females) cases. Anti-ubiquitin for Lewy body and anti-α-synuclein immunostaining on adjacent slices were analyzed in QuPath and [ 18 F]nifene binding was quantified in OptiQuant. Subiculum had greater [ 18 F]nifene binding (51% to 85%) compared to HP in all subjects. Significantly higher [ 18 F]nifene binding (>250%) was seen in PD SUB and PD HP compared to CN in both males and females. The grey matter (GM) to white matter (WM) ratio in PD=3.53 while CN=1.33, a >150% increase in PD. Binding of [ 18 F]nifene to GM and WM individually was >250% greater in PD compared to CN. Male CN exhibited an increase while and male PD exhibited a significant decrease in [ 18 F]nifene binding with aging, while females did not exhibit significant differences. In summary, α4β2* nAChR measured by [ 18 F]nifene is significantly upregulated in the PD HP and SUB. This increased [ 18 F]nifene binding may be of diagnostic value using PET imaging.